CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO., LTD. is an innovative biopharmaceutical enterprise focusing on the R&D of serum-free continuous animal cell culture technology and new biological drugs. The company successfully developed a new generation of thrombolytic drug rhTNK-tPA ( recombinant human TNK tissue-type plasminogen activator ), which is used for the treatment of acute myocardial infarction (AMI). In February 2022, the company was successfully merged into CSPC Pharmaceutical Group Limited (stock code: 1093). rhTNK-tPA will join forces with CSPC's high-quality products in the field of cardiocerebral vascular disease, and save more patients' lives. With the Group's strength in marketing and promotion, rhTNK-tPA will achieve the goal of becoming the top brand of thrombolytic drugs worldwide !